HER2-positive breast cancer has a distinctive biology, wherein amplification of the HER2 oncogene leads to a cascade of downstream effects. While in the past this distinctive biology was associated with a higher risk of recurrence and impaired long-term outcome, our current understanding of this ...
[4] Pérez-García JM, et al Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: the DEBBRAH trial. Neuro Oncol 2023;25:157-66 [5]Abelman RO, Spring L, Fell GG, et al. Sequential use of antibody-drug conjugate after antibody-drug ...
[6]Arab A.,Yazdian-RobatiR.,BehravanJ. HER2-Positive Breast Cancer Immunotherapy: A Focus on Vaccine Development. Arch. Immunol Ther. Exp. 2020;68:2. [7]D’AmatoV.,RaimondoL.,FormisanoL.,etal. Mechanisms oflapatinibresistance in HER2-driven breast cancer. Cancer Treat. Rev. 2015;41:87...
Clinical trials are needed to support the ASCO/CAP panel’s recommendation to expand the definition of HER2-positive breast cancer. Only such trials can prove that anti-HER2 therapy is effective for patients with tumors defined as HER2 positive since 2013, but HER2 negative before that time, ...
[2] Gianni, L. et al. Neoadjuvant and adjuvant trastuzumab in patients with HER2 positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet Oncol. 15, 640–647 (2014).[3] Wu, J. et al. Neoadjuvant ...
HER2-Positive Breast Cancer In about 20% of breast cancers, the cells make too much of a protein known as HER2. These cancers tend to be aggressive and fast-growing. For women with HER2-positive breast cancers, the targeted drugtrastuzumab(Herceptin) has been shown to dramatically reduce the...
Our study should be viewed in the context of two other trials. The Japanese TRIGGER trial demonstrated a survival benefit of trastuzumab for patients with HER2-positive gastric cancer and limited lymph node metastases. Addition...
The overexpression of human epidermal growth factor receptor-2 (HER2) results in a biologically and clinically aggressive breast cancer (BC) subtype. Since the introduction of anti-HER2 targeted agents, survival rates of patients with HER2-positive metastatic BC have dramatically improved. Currently, ...
HER2‐positive breast cancerT‐DM1trastuzumabtucatinibBackground Brain metastases (BrM) incidence is 25% to 50% in women with advanced human epidermal growth factor receptor 2 (HER2)﹑ositive breast cancer. Radiation and surgery are currently the main local treatment approaches for central nervous ...
The long-sought discovery of HER2 as an actionable and highly sensitive therapeutic target was a major breakthrough for the treatment of highly aggressive HER2-positive breast cancer, leading to approval of the first HER2-targeted drug — the monoclonal antibody trastuzumab — almost 25 years ago....